




PHARMACEUTICAL 2023

Stoke Therapeutics Inc.
Rank 173 of 446





PHARMACEUTICAL 2023

Stoke Therapeutics Inc.
Rank 173 of 446

The relative strengths and weaknesses of Stoke Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Stoke Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Stoke Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 89% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	244,070
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,394
Liabilities, Non-Current	39,824
Other Assets	5,322
Other Compr. Net Income	-1,007
Other Expenses	0
Other Liabilities	0
Other Net Income	3,289
Other Revenues	12,405
Property and Equipment	6,675
Research and Development	77,837
Selling, General and Administrative Expense	38,924

Output Variable	Value in 1000 USD
Assets	256,067
Liabilities	71,218
Expenses	116,761
Revenues	12,405
Stockholders Equity	184,849
Net Income	-101,067
Comprehensive Net Income	-101,570
Economic Capital Ratio	132%